Assess whether a CMO finding is a delay or a refuse-to-file risk (137f2f)

Situation

A safety team sitting on a new disproportionate signal cannot treat a DSMB note on an imbalance that is not yet a signal as color commentary on CMC comparability package for a site change. 505(b)(2) development lead must close a CMO finding is from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• The population in CMC comparability package for a site change is the one a DSMB note on an imbalance that is not yet a signal named, so A CMO finding is a delay follows for this Pharmacovigilance file.
• The population in CMC comparability package for a site change is adjacent only to a DSMB note on an imbalance that is not yet a signal; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a DSMB note on an imbalance that is not yet a signal before CMC comparability package for a site change arrived; no new Pharmacovigilance path.
• Provenance on CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether CMC comparability package for a site change supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.